Updated on 23 July 2012
Singapore: Australian infectious disease therapy and vaccine development company BioDiem received positive results from formal studies of its BDM-E eye disease drug. The results were presented at the International Society for Eye Research (ISER) meeting held in Berlin, Germany, between July 21 and 22. The ISER convenes leading researchers and clinicians in the area of eye disease.
BDM-E has received orphan drug designation from the US Food & Drug Administration (FDA) for the treatment of the inherited degenerative eye disorder retinitis pigmentosa (RP).
The eye research results presented at the ISER Conference confirm the potential of BDM-E. The results were as follows:
1) BDM-E was found to reduce formation of abnormal blood vessel growth
2) BDM-E was found to reduce the signs of damage typical to retinitis pigmentosa
3) BDM-E was shown to improve the function of the retina and inhibit the death of cells imperative for sight
BioDiem has a research agreement with the Foundation Fighting Blindness, a leading US eye research advocate, to test BDM-E in a pre-clinical model of RP, a genetic cause of blindness without effective treatment options.